Pelthos Therapeutics Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pelthos Therapeutics Inc. (NYSE American: PTHS) on May 21, 2026, covering events occurring between April 10, 2026, and May 18, 2026. The Company is an emerging growth company incorporated in Nevada.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or liquidity metrics. The only specific financial figure disclosed relates to a separation payment obligation of $430,000.00 for the former Chief Financial Officer.
Material Changes
- Change in Certifying Accountant: The Audit Committee dismissed CBIZ CPAs P.C. as the independent registered public accounting firm effective May 16, 2026. CBIZ had audited the financial statements for the fiscal year ended December 31, 2025, with no adverse opinions, disclaimers, or disagreements reported.
- Appointment of New Auditor: Grant Thornton LLP was engaged as the new independent registered public accounting firm for the fiscal year ending December 31, 2026, and related interim periods.
- Executive Departure: Francis Knuettel II was terminated from his roles as Chief Financial Officer, Treasurer, and Secretary, effective April 10, 2026. A Separation and Release Agreement was executed on May 15, 2026.
Guidance, Outlook, and Unusual Items
The filing contains no forward-looking guidance, revenue outlook, or management commentary regarding future business operations. The primary unusual item is the executive separation agreement, which includes:
- Payment of earned but unpaid compensation and reimbursement of business expenses.
- Separation pay equal to 12 months of base salary ($430,000.00).
- Acceleration of vesting for stock options and restricted stock units (RSUs) that would have vested over the 12-month period following the separation date.
- The agreement is subject to a 7-day revocation period and becomes effective upon expiration of this period without revocation.
Investor Verification Checklist
- Verify the effective date of the Separation Agreement following the 7-day revocation period to confirm the $430,000 liability and equity acceleration are binding.
- Review the transition plan between CBIZ CPAs P.C. and Grant Thornton LLP to ensure no disruption to the 2026 audit timeline.
- Confirm the appointment of a permanent replacement for the Chief Financial Officer, Treasurer, and Secretary roles.
- Check subsequent filings for the impact of the accelerated equity vesting on the Company's share count and dilution.